Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos

Detalhes bibliográficos
Ano de defesa: 2019
Autor(a) principal: Rodrigues, Talita
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
dARK ID: ark:/26339/001300000vnnt
Idioma: por
Instituição de defesa: Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://repositorio.ufsm.br/handle/1/20908
Resumo: Schizophrenia is a chronic and debilitating disorder that affects about 1% of the population. Chronic use of antipsychotics, especially typical ones, used to treat schizophrenia, causes as adverse effect debilitating motor disorder (dyskinesia). Tardive dyskinesia affects 20% to 40% of patients, and is characterized by repetitive and involuntary movements involving mainly the oro-buco-facial region. There is no effective treatment either for avoiding or treating tardive dyskinesia. Therefore, it is important to search for new treatments and/or therapeutic adjuvants that can be clinically useful. Silibinin is the majoritary active constituent of silymarin, which is a flavonoid isolated from the seeds of Silybum marianum (L.) Gaerth, which has antioxidant action and potential neuroprotective effect, even in animal models of motor diseases. Thus, male mice were treated with vehicle (0,9% NaCl), haloperidol (1.25 mg / kg, i.p.), silibinin (20 mg / kg, i.p.) and haloperidol (1.25 mg / kg, i.p.) + silibinin (20 mg / kg, i.p.) intraperitoneally for 28 consecutive days. Behavioral quantification (vacuous chewing movements - VCMs, number of crossings and rearings in the open field and time of immobility) was performed every 7 or 14 days during the experimental period. The biochemical parameters of oxidative stress were evaluated in cerebral structures (cortex, striatum and region containing the substantia nigra), liver and kidney. Haloperidol caused orofacial dyskinesia by increasing the prevalence and frequency of VCMs without altering the other behavioral parameters evaluated. Negative correlations were found between the numbers of crossings or rearings with VCMs and a positive correlation between immobility time and VCMs. Silibinin did not avoid the effects of haloperidol on behavioral parameters. In addition, neither haloperidol nor silibinin caused changes in oxidative stress parameters. A positive correlation was found between the number of VCMs and the non-protein thiol content in the cortex of mice. No significant results were found in Na+/K+/ ATPase activity in the different brain structures. In conclusion, the data of this study demonstrates that in mice also it is possible to verify the increase in the frequency of VCMs only in a percentage of animals mimicking which occurs with the patients. Furthermore, although silibinin did not avoid the VCMs in mice its combined treatment with haloperidol seems not cause signals of oxidative stress markers in animals.
id UFSM_cb0a3dab16ece8d6404f24492fddd8cd
oai_identifier_str oai:repositorio.ufsm.br:1/20908
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongosEffect of silibinin on a model of orofacial dyskinesia induced by haloperidol in miceMovimento de mascar no vazioCampo abertoImobilidadeEstresse oxidativoVacuous chewing movementsOpen fieldImmobilityOxidative stressCNPQ::CIENCIAS DA SAUDE::FARMACIASchizophrenia is a chronic and debilitating disorder that affects about 1% of the population. Chronic use of antipsychotics, especially typical ones, used to treat schizophrenia, causes as adverse effect debilitating motor disorder (dyskinesia). Tardive dyskinesia affects 20% to 40% of patients, and is characterized by repetitive and involuntary movements involving mainly the oro-buco-facial region. There is no effective treatment either for avoiding or treating tardive dyskinesia. Therefore, it is important to search for new treatments and/or therapeutic adjuvants that can be clinically useful. Silibinin is the majoritary active constituent of silymarin, which is a flavonoid isolated from the seeds of Silybum marianum (L.) Gaerth, which has antioxidant action and potential neuroprotective effect, even in animal models of motor diseases. Thus, male mice were treated with vehicle (0,9% NaCl), haloperidol (1.25 mg / kg, i.p.), silibinin (20 mg / kg, i.p.) and haloperidol (1.25 mg / kg, i.p.) + silibinin (20 mg / kg, i.p.) intraperitoneally for 28 consecutive days. Behavioral quantification (vacuous chewing movements - VCMs, number of crossings and rearings in the open field and time of immobility) was performed every 7 or 14 days during the experimental period. The biochemical parameters of oxidative stress were evaluated in cerebral structures (cortex, striatum and region containing the substantia nigra), liver and kidney. Haloperidol caused orofacial dyskinesia by increasing the prevalence and frequency of VCMs without altering the other behavioral parameters evaluated. Negative correlations were found between the numbers of crossings or rearings with VCMs and a positive correlation between immobility time and VCMs. Silibinin did not avoid the effects of haloperidol on behavioral parameters. In addition, neither haloperidol nor silibinin caused changes in oxidative stress parameters. A positive correlation was found between the number of VCMs and the non-protein thiol content in the cortex of mice. No significant results were found in Na+/K+/ ATPase activity in the different brain structures. In conclusion, the data of this study demonstrates that in mice also it is possible to verify the increase in the frequency of VCMs only in a percentage of animals mimicking which occurs with the patients. Furthermore, although silibinin did not avoid the VCMs in mice its combined treatment with haloperidol seems not cause signals of oxidative stress markers in animals.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESA esquizofrenia é um distúrbio crônico e debilitante que afeta cerca de 1% da população. A utilização crônica de antipsicóticos, principalmente os antipsicóticos típicos, utilizados para o tratamento da esquizofrenia, causa, como efeito adverso, distúrbios motores debilitantes (discinesia). A discinesia tardia afeta de 20% a 40% dos pacientes, e é caracterizada por movimentos repetitivos e involuntários que envolvem principalmente a região oro-buco-facial. Não existe um tratamento eficaz para evitar e/ou tratar a discinesia tardia. Desta forma, é importante a busca por novos tratamentos e/ou adjuvantes terapêuticos que possam ser utilizados clinicamente. A Silibinina é o constituinte ativo majoritário da silimarina, que é um flavonóide isolado das sementes de Silybum marianum (L.) Gaerth, o qual possui ação antioxidante e potencial efeito neuroprotetor, inclusive em modelos animais de doenças motoras. O objetivo deste trabalho foi avaliar o efeito da silibinina em um modelo de discinesia orofacial induzida por haloperidol em camundongos. Dessa forma, camundongos machos foram tratados com veículo (NaCl 0,9%), haloperidol (1,25 mg / kg, i.p.), silibinina (20 mg / kg, i.p.) e haloperidol (1,25 mg / kg, i.p.) + silibinina (20 mg/ kg, i.p) intraperitonealmente durante 28 dias consecutivos. A quantificação comportamental (movimentos de mastigação vazios - MMVs, número de cruzamentos e levantamentos no campo aberto e tempo de imobilidade) foi realizada a cada 7 ou 14 dias durante o período experimental. Os parâmetros bioquímicos do estresse oxidativo foram avaliados em estruturas cerebrais (córtex, estriado e região contendo a substância negra), fígado e rim. O haloperidol causou discinesia orofacial aumentando a prevalência e a frequência de MMVs sem alterar os demais parâmetros comportamentais avaliados. Foram encontradas correlações negativas entre o número de cruzamentos ou levantamentos com MMVs e uma correlação positiva entre o tempo de imobilidade e os MMVs. A silibinina não evitou os efeitos do haloperidol nos parâmetros comportamentais. Além disso, nem o haloperidol nem a silibinina causaram alterações nos parâmetros de estresse oxidativo. Foi encontrada uma correlação positiva entre o número de MMVs e o teor de tiol não protéico no córtex de camundongos. Não foram encontrados resultados significativos na atividade da Na+/k+/ATPase nas diferentes estruturas cerebrais. Em conclusão, os dados deste estudo demonstram que, em camundongos, também é possível verificar o aumento na frequência de MMVs apenas em um percentual dos animais tratados mimetizando o que acontece em pacientes. Além disso, apesar de a silibinina não evitar os MMVs, o tratamento combinado com haloperidol não parece causar alterações em marcadores de estresse oxidativo nos animais.Universidade Federal de Santa MariaBrasilFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaCentro de Ciências da SaúdeFachinetto, Roseleihttp://lattes.cnpq.br/7203076675431306Wagner, CarolineRosemberg, Denis BroockRodrigues, Talita2021-05-14T18:51:32Z2021-05-14T18:51:32Z2019-03-11info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/20908ark:/26339/001300000vnntporAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2024-08-15T18:50:10Zoai:repositorio.ufsm.br:1/20908Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/PUBhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.bropendoar:2024-08-15T18:50:10Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
Effect of silibinin on a model of orofacial dyskinesia induced by haloperidol in mice
title Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
spellingShingle Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
Rodrigues, Talita
Movimento de mascar no vazio
Campo aberto
Imobilidade
Estresse oxidativo
Vacuous chewing movements
Open field
Immobility
Oxidative stress
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
title_full Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
title_fullStr Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
title_full_unstemmed Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
title_sort Efeito da silibinina em modelo de discinesia orofacial induzida pelo haloperidol em camundongos
author Rodrigues, Talita
author_facet Rodrigues, Talita
author_role author
dc.contributor.none.fl_str_mv Fachinetto, Roselei
http://lattes.cnpq.br/7203076675431306
Wagner, Caroline
Rosemberg, Denis Broock
dc.contributor.author.fl_str_mv Rodrigues, Talita
dc.subject.por.fl_str_mv Movimento de mascar no vazio
Campo aberto
Imobilidade
Estresse oxidativo
Vacuous chewing movements
Open field
Immobility
Oxidative stress
CNPQ::CIENCIAS DA SAUDE::FARMACIA
topic Movimento de mascar no vazio
Campo aberto
Imobilidade
Estresse oxidativo
Vacuous chewing movements
Open field
Immobility
Oxidative stress
CNPQ::CIENCIAS DA SAUDE::FARMACIA
description Schizophrenia is a chronic and debilitating disorder that affects about 1% of the population. Chronic use of antipsychotics, especially typical ones, used to treat schizophrenia, causes as adverse effect debilitating motor disorder (dyskinesia). Tardive dyskinesia affects 20% to 40% of patients, and is characterized by repetitive and involuntary movements involving mainly the oro-buco-facial region. There is no effective treatment either for avoiding or treating tardive dyskinesia. Therefore, it is important to search for new treatments and/or therapeutic adjuvants that can be clinically useful. Silibinin is the majoritary active constituent of silymarin, which is a flavonoid isolated from the seeds of Silybum marianum (L.) Gaerth, which has antioxidant action and potential neuroprotective effect, even in animal models of motor diseases. Thus, male mice were treated with vehicle (0,9% NaCl), haloperidol (1.25 mg / kg, i.p.), silibinin (20 mg / kg, i.p.) and haloperidol (1.25 mg / kg, i.p.) + silibinin (20 mg / kg, i.p.) intraperitoneally for 28 consecutive days. Behavioral quantification (vacuous chewing movements - VCMs, number of crossings and rearings in the open field and time of immobility) was performed every 7 or 14 days during the experimental period. The biochemical parameters of oxidative stress were evaluated in cerebral structures (cortex, striatum and region containing the substantia nigra), liver and kidney. Haloperidol caused orofacial dyskinesia by increasing the prevalence and frequency of VCMs without altering the other behavioral parameters evaluated. Negative correlations were found between the numbers of crossings or rearings with VCMs and a positive correlation between immobility time and VCMs. Silibinin did not avoid the effects of haloperidol on behavioral parameters. In addition, neither haloperidol nor silibinin caused changes in oxidative stress parameters. A positive correlation was found between the number of VCMs and the non-protein thiol content in the cortex of mice. No significant results were found in Na+/K+/ ATPase activity in the different brain structures. In conclusion, the data of this study demonstrates that in mice also it is possible to verify the increase in the frequency of VCMs only in a percentage of animals mimicking which occurs with the patients. Furthermore, although silibinin did not avoid the VCMs in mice its combined treatment with haloperidol seems not cause signals of oxidative stress markers in animals.
publishDate 2019
dc.date.none.fl_str_mv 2019-03-11
2021-05-14T18:51:32Z
2021-05-14T18:51:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/20908
dc.identifier.dark.fl_str_mv ark:/26339/001300000vnnt
url http://repositorio.ufsm.br/handle/1/20908
identifier_str_mv ark:/26339/001300000vnnt
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.br
_version_ 1847153452564611072